January 15 - 18, 2019
Abstract submission deadline: Thursday, November 8
Advance registration deadline: Tuesday, December 4
Tuesday, Jan. 15
Friday, Jan. 18
Targeting the TIGIT/CD226 axis in melanomaHassane M. Zarour, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Response and resistance to checkpoint blockade therapy
Overcoming immune resistance with rationally designed combination immunotherapyRoberta Zappasodi, Memorial Sloan Kettering Cancer Center, New York, New York
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade* Livnat Jerby-Arnon, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts
Melanoma evolves complete immunotherapy resistance through acquisition of a hypermetabolic phenotype* Arthur Liu, The University of Texas MD Anderson Cancer Center, Houston, Texas
Distinct immune and molecular features of melanoma brain metastasesMichael A. Davies
Concepts of cancer and Metastasis: Historical perspective Claire Lugassy, Institut Curie, Paris, France
Impact of tumor-resident dendritic cells on anti-tumor immune responsesStefani Spranger, MIT Koch Institute for Integrated Cancer Research, Cambridge, Massachusetts
Non-genomic BAP1 aberrancy drives highly aggressive cutaneous melanoma phenotype*Scott Woodman, The University of Texas MD Anderson Cancer Center, Houston, Texas
Epigenetic silencing of CDR1as drives IGF2BP3-mediated melanoma invasion and metastasis*Douglas Hanniford, NYU Langone Health, New York, New YorkFree Time (Lunch on Own)12:30-2:30 p.m.Plenary Session 3:
Melanoma MetabolismSession Chair: Paul B. Chapman, Memorial Sloan Kettering Cancer Center, New York, New York2:30-4:30 p.m.
Elevated endogenous SDHA drives pathological metabolism in highly metastatic uveal melanomaChandrani Chattopadhyay, The University of Texas MD Anderson Cancer Center, Houston, Texas
Tumor cell oxidative metabolism as a barrier to antitumor immunity in melanomaGreg M. Delgoffe, University of Pittsburgh, Pittsburgh, PA
Targeting melanoma metabolism to overcome resistance to treatment Paul B. Chapman
Unique lipid metabolite profiling in BRAFV600E inhibitor drug-resistant melanoma and their potential as drug target*Meng-Ting Chang, Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan
The glutaminase inhibitor CB-839 potentiates anti-melanoma activity of standard-of-care targeted therapies and immunotherapies*Vashisht Yennu Nanda, The University of Texas MD Anderson Cancer Center, Houston, TexasPoster Session A / Reception4:30-7 p.m.Thursday, Jan. 17Continental Breakfast7-8 a.m.Plenary Session 4:
Early Melanoma Detection and PreventionSession Chair: Sancy A. Leachman, Oregon Health & Science University, Portland, Oregon8-10 a.m.
The war on melanoma: Oregon’s early detection experimentSancy A. Leachman
Preventing melanoma progression through a genomic approachMarianne Berwick, University of New Mexico Health Sciences Center-Albuquerque, Albuquerque, New Mexico
Opportunities and challenges in melanoma early detectionDavid Polsky, New York University School of Medicine, New York, New York
The role of keratinocyte desmoglein 1 in shaping the melanoma tumor niche*Hope Burks, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
Identifying the molecular and environmental factors mediating transformation of melanocyte stem cells to melanoma*Andrew White, Cornell University, Ithaca, New YorkBreak10-10:30 a.m.Plenary Session 5: Non-Cutaneous Melanoma and Rare Cutaneous SubtypesSession Chair: Richard D. Carvajal, Columbia University Medical Center, New York, New York10:30 a.m.-12:30 p.m.
Immunosensitivity and resistance in advanced uveal melanomaRichard D. Carvajal
Novel genomic and transcriptomic aberrations in acral compared to sun-exposed melanomasRuth Halaban, Yale University, New Haven, ConnecticutKahn Rhrissorrakrai, IBM Thomas J. Watson Research Center, Yorktown Heights, NY
The landscape of mucosal melanoma: A long way to goJun Guo, Peking University Cancer Hospital & Institute, Beijing, China
Pharmacological targeting of Gq reveals new pathways in uveal melanoma*
Michael Onken, Washington University School of Medicine, Saint Louis, MissouriPoster Session B / Lunch12:30-3 p.m.Plenary Session 6: Targeting Driver Pathways Beyond BRAF Session Chair: Marcus W. Bosenberg, Yale University, New Haven, Connecticut3-5 p.m.
Defining the actionable genomeDavid B. Solit, Memorial Sloan Kettering Cancer Center, New York, New York
Therapeutic opportunities gleaned from melanoma's unique pathogenesisDavid E. Fisher, Massachusetts General Hospital, Boston, Massachusetts
Role of autophagy in cancerEileen P. White, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Identifying new immune targets in malignant melanomaMarcus W. BosenbergBreak5-5:15 p.m.Special Session: Proffered Talks from Highly Rated AbstractsSession Chairs: Mario Sznol, Yale Cancer Center, New Haven, Connecticut, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, New York5:15-6:30 p.m.
Understanding the role of myddosome dynamics in melanoma using live cell imaging*Bridget Kreger, AstraZeneca, Waltham, Massachusetts
Regulation of the tumor suppressive miR-29 family by oncogenic MAPK signaling in melanoma*Olga Vera, Moffitt Cancer Center, Tampa, Florida
PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas*Minjung Kim, University of South Florida, Tampa, Florida
Defining isoform-specific roles for AKTs in BRAFV600E-driven melanoma*Jaymes Farrell, Tufts University, Boston, Massachusetts
Monitoring of melanoma progression utilizing multi-platform biomarkers of blood cell-free DNA*David Hoon, John Wayne Cancer Insitute, Santa Monica, California
Friday, Jan. 18Continental Breakfast7-8 a.m.Plenary Session 7: Intersection of the Tumor and Immune MicroenvironmentSession Chair: Suzanne L. Topalian, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland8-10 a.m.
Translating immunotherapy from melanoma to other skin cancersSuzanne L. Topalian
Intrinsic tumor genomic and metabolic factors leading to immunoresistancePatrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas
Myeloid cell melanoma interfaceKarolina Palucka, The Jackson Laboratory, Farmington, Connecticut
CD74 regulated inflammatory pattern is associated with TIL growth and favorable response to adoptive immunotherapy*Suhendan Ekmekcioglu,
The University of Texas MD Anderson Cancer Center, Houston, Texas
Specific activation of the G protein-coupled estrogen receptor inhibits melanoma and other cancers and potentiates immune and targeted therapies*Todd Ridky, University of Pennsylvania, Philadelphia, PennsylvaniaBreak10-10:30 a.m.Plenary Session 8: BRAF and MEK Resistance
Session Chair: Jeffrey A. Sosman, Northwestern University, Chicago, Illinois10:30 a.m.-12:30 p.m.
Are there non-immune targets in the BRAFV600 WT melanoma patient?Jeffrey A. Sosman
Targeting MEK1/2 inhibitor resistance in RAS-mutated cancersMartin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Strategies to overcome MAPK inhibitor resistanceRoger S. Lo, University of California, Los Angeles, California
Sleeping Beauty mutagenesis reveals a Src-dependent DBL GEF family signaling mechanism driving MAPK inhibitor resistance in BRAF mutant melanoma*Christopher Stipp, University of Iowa, Iowa City, Iowa
Comparative screening of skin-derived NCSCs, melanocytes, and melanoma developmental programs reveals LPAR1 in MAPKi resistance*Vito Rebecca, Wistar Institute, Philadelphia, Pennsylvania Closing Remarks12:30-12:45 p.m.
*short talks from proffered abstracts